content top

Choroidal Neovascular Membrane in Children

SCIENTIFIC POSTER 2016_Choroidal Neovascular Membrane in Children Maha M. Elshafei Case 1: A case of seven-year-old girl who presented to the eye clinic complaining of decreased vision in both eyes. Examination showed bilateral active choroidal neovascular membrane in the macular area, which was, treated with multiple intravitreal injections of Ranibizumab. Screening of the family showed bilateral Vitilliform maculopathy in the younger...

Read More

Idiopathic Choroidal Neovascular Membrane in a 9 Years Old Child

Veronica Ramos Camara_SCIENTIFIC POSTER 2015 An 8-years-old boy was referred to our service for evaluation of decreasing vision in his right eye. Personal Background: Patent ductus arteriosus surgery. His family denied history of trauma or inflammation. His best corrected visual acuity in his right eye was light perception and 20/20 in his left eye. Retinography showed subfoveal choroidal neovascular membrane (CNVM) with subretinal...

Read More

Macular Translocation with 360-Degree Retinotomy for the Managment of Retinal Pigment Epithelial Tear: 3 Years Results

http://www.evrs.eu/medias/2009/congress/Surgery.flv Authors: Barbara Parolini, Grazia Pertile, Verona, Italy To determine whether macular translocation with 360-degree retinotomy can stabilize and / or improve visual acuity in patients with retinal pigment epithelium (RPE) tear, given the increasing number of reports on this complication following vascular endothelial growth factor (VEGF)-modulating therapy. Methods: Prospective...

Read More

Submacular Surgery for Myopic Choroidal Neovascular Membrane

http://www.evrs.eu/medias/2009/congress/Surgery.flv Author: Khaled El Rakhawy, Cairo, Egypt Advantages: In selected cases of myopic CNVM, surgical removal gives better visual outcome and relieves the patient from metamorphopsia as well as from the need to have many repeated injections with only limited improvement or merely stabilization of vision. Large membranes are particularly suitable for this approach. Methods: After complete...

Read More

There Could Still Be a Place for Surgical CNV Removal

http://www.evrs.eu/medias/2009/congress/Surgery.flv Author: Klaus Lucke, Bremen, Germany Introduction: Surgical removal of subfoveal CNVs was practiced widely in the 1990s for the treatment of AMD and other exudative maculopathies. Since it virtually always left a large subfoveal RPE defect the visual results were by and large disappointing and the Submacular Surgery Trial (SST) showed that no statistically significant improvement in vision...

Read More

Is Surgical Ablation of Blood Neovessels Still Useful?

http://www.evrs.eu/medias/2009/congress/Surgery.flv Author: Jean-Paul Amar, Cannes, France Subretinal surgery has slowly disappeared but 75% of eyes with a subretinal heamatoma are lost. The subretinal drainage of the blood and the surgical ablation of the blood neovessels seem to remain still useful with a quite low rate of complications.

Read More

Epimacular Brachytherapy for Wet AMD: 24 Months Results

http://www.evrs.eu/medias/2009/congress/Surgery.flv Authors: TL Jackson, M Farah, JP Duprat, M Avila, GY Fujii, J Rossi, A Santos, R Palank , J Nau, London, UK Advantages: Epimacular brachytherapy (EMB) offers a novel, durable, costeffective treatment for age-related macular degeneration. Methods: Patients with classic, mixed or occult choroidal neovascularisation (CNV) underwent a pars plana vitrectomy followed by 24 Gy beta irradiation...

Read More

Combined Treatment of Retinal Pigment Epithelium Serous Detachment in the Macular Region Caused by Age-Related Macular Degeneration

http://www.evrs.eu/medias/2009/congress/Surgery.flv Authors: Victor N. Kazaykin, Igor A. Malov, Yekaterinburg, Russia Advantages: Combination of laser retinopuncture and 25G endovitreal surgery provides a possibility to obtain attachment of retinal pigment epithelium serous detachment (RPE SD), caused by ARMD, in the macular region in its combination with posterior hyaloid detachment. Methods: After limiting retinal lasercoagulation at...

Read More

Spectral OCT Determined Anti-VEGF Treatment

http://www.evrs.eu/medias/2009/congress/When-Re-Treating.flv Authors: Janusz Michalewski, Slawomir Cisiecki, Dominik Odrobina, Krzysztof Dziegielewski, Zbigniew Pikulski, Zofia Michalewska, Maciej Bednarski, Jerzy Nawrocki, Lodz, Poland Advantages: Spectral domain OCT determined anti- VEGF therapy enabled the reduction of number of injections. Moreover Spectral OCT enabled to determine some prognostic factors for anti- VEGF...

Read More

Assessment of CNV Activity with a New Activity

http://www.evrs.eu/medias/2009/congress/When-Re-Treating.flv Authors: Sengul Ozdek, Cuneyt Ozmen, Berati Hasanreisoglu, Ankara, Turkey Advantages: A new activity scoring (AS) for assessment of the neovascular ARMD activity is defined. AS supplies standardization for the assessment of the lesion activity after anti-VEGF therapy. Methods: 52 eyes with neovascular ARMD treated with anti- VEGF agents were involved. The AS is based on 1) fluid...

Read More

Classification for OCT Findings in CNV Secondary to AMD

http://www.evrs.eu/medias/2009/congress/When-Re-Treating.flv Author: Arwa Azmeh, Damascus, Syria Advantages: A classification of retinal and subretinal morphological changes based on OCT findings was suggested to be used in follow up of activity of CNV secondary to AMD after treatment, and for making the decision of retreatment. Methods: OCT scans through CNV secondary to AMD using Zeiss stratus OCT 3000 were analyzed. The OCT findings were...

Read More

Definition and Management of Non-Responders to Anti-VEGF for CNV

http://www.evrs.eu/medias/2009/congress/When-Re-Treating.flv Authors: Sengul Ozdek, Cuneyt Ozmen, Berati Hasanreisoglu, Ankara, Turkey Advantages: To define the nonresponders of CNV to anti-VEGF treatment clearly so that unnecessary treatments with a costly agent can be prevented. Methods: A mini questionnaire with 7 items was send to the retina specialist in Turkey via e-mail. The questions were related with the definition of...

Read More

One Year Study of Intravitreal Avastin and Combination with Avastin and Photodynamic Therapy in Neovascular Age Related Macular Degeneration

http://www.evrs.eu/medias/2009/congress/Combined-Treatments.flv Author: Taehyuk Koh, South Korea Advantages: To evaluate the one year outcome for monotherapy of avastin and combined therapy of avastin plus photodynamic therapy (PDT). Methods: Monotherapy group was received avastin 3 times every 6 weeks. In combination group, we started intravitreal avastin one week before and after PDT in the same way. In 49 eyes, we evaluated vision,...

Read More

Analysis of Rate of Change in Macular Thickness in Combination Photodynamic Therapy and Bevacizumab Treatment for Exudative Age-Related Macular Degeneration (the VIA Study)

http://www.evrs.eu/medias/2009/congress/Combined-Treatments.flv Authors: Raimondo Forte, Naples, Italy; Michael J. Potter, Cheryl Claudio, Shelagh M. Szabo, Vancouver, Canada Advantages: To obtain a greater improvement after treatment of choroidal neovascularization (CNV) due to age-related macular degeneration (AMD). Methods: Prospective, randomized, double masked, controlled, interventional study. Thirty five eyes (35 patients) presenting...

Read More

Triple Therapy for Exudative AMD

http://www.evrs.eu/medias/2009/congress/Combined-Treatments.flv Authors: Raimondo Forte, Paola Bonavolontà, Naples, Italy; Jean Paul Adenis, Pierre-Yves Robert, Limoges, France Advantages: To reduce the number of retreatments with intravitreal anti- VEGF in exudative age related macular degeneration (AMD). Methods: We evaluated all eyes with exudative AMD treated with bevacizumab or ranibizumab in monotherapy and in association with...

Read More

Randomized, Double Blind, Controlled Study with Verteporfin Photodynamic Therapy and Intravitreal Triamcinolone(IVTA) vs Triple Theraphy with Verteporfin Photodynamic Therapy, Intravitreal Triamcinolone and Intravitreal Ranibizumab in Patients with Subfoveal Choroidal Neovascularization (CNV) Secondary

http://www.evrs.eu/medias/2009/congress/Combined-Treatments.flv Authors: Rosa Maria Romero-Castro, Alfredo Morales, H. Quiroz-Mercado, Mexico Advantages: New modality treatmens are needed to increase effectiveness and reduce number of retreatmens in AMD patients. Triple therapy with PDT, intravitreal triamcinolone and intravitreal ranibizumab can be with less number of treatments and they’re for less cost a safe treatment option for...

Read More

Tailored Anti VEGF for ARMD

http://www.evrs.eu/medias/2009/congress/Anti-VEGF-Alone.flv Author: Ron A. Adelman, New Haven, CT, USA Advantages: Reduction of number of injection, improving compliance Methods: Injection of anti VEGF monthly for 3 months. After three months decision for treatment is based on OCT. Effectiveness / Safety: Improved patient satisfaction.

Read More

Tailored Anti-VEGF for ARMD

http://www.evrs.eu/medias/2009/congress/Anti-VEGF-Alone.flv Authors: Ivan Fiser, Frantisek Benda, Prague, Czech Republic Advantages: Tailored therapy with Avastin is an effective treatment of wet AMD. It can reduce the number of applications and save the patients´ money, thus enables more patients to be treated. There are potential super responders to Avastin in whom a single injection is a sufficient treatment. Methods: 274 eyes of 270...

Read More

Tritherapy Using Avastin, Visudyne and Triamcinolone as Treatment of Neovascular AMD

Guy l’Helgoualch, MD (Brest, France) PURPOSE: To check using Avastin in intravitreous injection reduces the surface and the thickness of the neovascular membrane. To check improving the effect of PDT and reducing the side effects increases the final visual acuity. To verify this protocol of tritherapy reduces the number of treatment during the period of follow-up. METHODS: The population of patients includes the same proportion of...

Read More

Large Case Series of Different Types of CNV after Combination Treatment (PDT with Intravitreal Triamcinolone)

Albert J. Augustin, MD (Sulzfeld, Germany), Indre Offermann, MD (Karlsruhe, Germany), Stephan Puls, MD (Karlsruhe, Germany), Frank H.J. Koch, MD (Frankfurt am Main, Germany), Ursula Schmidt-Erfurth, MD (Vienna, Austria)* PURPOSE: To assess the treatment and outcome of patients with CNV treated with PDT combined with intravitreal triamcinolone (TA). METHODS: Patients (n? 307) suffering from CNV (76.2% subfoveal, 12.1% juxtafoveal, 11.7%...

Read More

Combination Therapy of Photodynamic Therapy with Verteporfin and Intravitreal Pegaptanib in the Management of Exudative ARMD

Asheesh Tewari, MD (St. Louis, MO), Rajendra S. Apte, MD, PhD (St. Louis, MO)* PURPOSE: To examine outcomes of a group of previously treatment naïve patients treated with combined photodynamic therapy with verteporfin and intravitreal pegaptanib for choroidal neovascularization secondary to ARMD. METHODS: Retrospective review of ten eyes of ten consecutive patients with CNV secondary to ARMD. These patients had  not received  any prior...

Read More

Six-month Results of a Randomized, Double-masked, Controlled Trial of Intravitreal Triamcinolone as an Adjunct to Photodynamic Therapy in Predominantly Classic Neovascular Age-related Macular Degeneration: The Canadian RETINA Study

http://www.evrs.eu/medias/2006/congress/Six-month-Results-of-a-Randomized,-Double-masked,-Controlled-Trial-of-Intravitreal-Triamcinolone-as-an-Adjunct-to-Photodynamic-Therapy-in-Predominantly-Classic-Neovascular-Age-related-Macular-Degeneration:-The-Canadian-RETINA-Study.swf David Maberley, MD, FRCSC, MSc (Vancouver, Canada),* PURPOSE: To compare safety data and ETDRS visual acuity outcomes data for one-hundred subjects with predominantly...

Read More

Expression of VEGF and PEDF in Choroidal Neovascular Membranes Following Verteporfin Photodynamic Therapy

Olcay Tatar, (Tuebingen, Germany), Annemarie Adam, (Tuebingen, Germany), Kei Shinoda, MD, PhD (Tokyo, Japan), Peter Stalmans, MD, PhD (Leuven, Belgium), Claus Eckardt, MD (Frankfurt, Germany), Matthias Lüke, MD (Tuebingen, Germany), Karl Ulrich Bartz-Schmidt (Tuebingen, Germany), Salvatore Grisanti, MD (Tuebingen, Germany) PURPOSE: To examine the impact of photodynamic therapy (PDT) on pigment epithelium derived factor (PEDF) expression...

Read More

Intravitreal Combination of Kenacort and Avastin (Ken-Av) for Choroidal Neovascular Age-related Macular Degeneration

Panos Stergiou, (Thessaloniki, Greece), Kostantinos Malamos, MD (Thessaloniki, Greece), Efstathios Dragiotis, MD (Thessaloniki, Greece), Anastasios Felekidis, MD (Thessaloniki, Greece), Tania Karagiani, MD (Thessaloniki, Greece), Stavros Dimitrakos, MD (Thessaloniki, Greece) PURPOSE: To investigate whether combined intravitreal use of triamcinolone (Kenacort) and bevacizumab (Avastin) can prolong the beneficial effect and reduce the need...

Read More

The Effect of Kenalog as Adjunctive Treatment to Visudyne in Minimally Classic and Occult Neovascular AMD: A Prospective, Randomized Clinical Trial

http://www.evrs.eu/medias/2006/congress/The-Effect-of-Kenalog-as-Adjunctive-Treatment-to-Visudyne-in-Minimally-Classic-and-Occult-Neovascular-AMD:-A-Prospective,-Randomized-Clinical-Trial.swf Tom Sheidow, MD, FRCS(C) (London, Canada), Varun Chaudhary, MD (London, Canada), Phil Hooper, MD, FRCSC (London, Canada), Alex Mao, MD (London, Canada) PURPOSE: To evaluate the mean change is ETDRS visual acuity score from baseline and the number of...

Read More

Combined Intravitreal Triamcinolone with Photodynamic Therapy for the Treatment of Choroidal Neovascularization in Age Related Macular Degeneration

http://www.evrs.eu/medias/2006/congress/Combined-Intravitreal-Triamcinolone-with-Photodynamic-Therapy-for-the-Treatment-of-Choroidal-Neovascularization-in-Age-Related-Macular-Degeneration.swf Catherine Favard, MD (Paris, France), Valerie Krivosic, MD (Paris, France), Lucie Machado, DO (Paris, France), Michael Assouline, MD, PhD (Paris, France), Catherine Francais, MD (Paris, France) PURPOSE: To determine whether photodynamic therapy (PDT)...

Read More

Hypericin-enhanced Argon Laser Photocoagulation for Subfoveal Choroidal Neovascular Membrane in Age-related Macular Degeneration

Gÿng.sr Sobaci, MD (Ankara, Turkey), Melih Osman Çeylan, MD (Ankara, Turkey), Sayih Altun, MD (Ankara, Turkey), Seçkin Aykas, MD (Anakar, Turkey), Mehmmet Zeki Bayraktar, MD (Ankara, Turkey) PURPOSE: We previously showed that hypericin, the most powerful natural photoactive pigment can induce development of photothrombosis in the choriocapillaries when activated with argongreen laser at light fluences causing subthreshold burn Efficacy...

Read More

Anecortave Acetate Clinical Update

Peter K. Kaiser, MD (Cleveland, OH)* PURPOSE: An update of the baseline characteristics of the Anecortave Acetate Risk Reduction Study (AART, C-02-60) evaluating the efficacy and safety of posterior juxtascleral administrations (PJD) of anecortave acetate versus sham in patients at risk for developing sightthreatening choroidal neovascularization (CNV), and of the combination study with an anti-VEGF antiangiogenic agent (Bridge...

Read More

Effect on High Contrast Discriminated Target Central Fields of Photodynamic Therapy with Vertporphyrin for CNVM Due to AMD

Stephen H. Sinclair, MD (Media, PA),* Weiye Li, MD (Media, PA), Peter Presti, (Media, PA)* PURPOSE: Vision outcomes for treatment of AMD CNVM have been previously evaluated using visual acuity with severe limitations. Central visual field testing with discriminated targets appears to offer significant advantages. METHODS: In this cohort, 31 eyes of 29 patients undergoing PDT with intravitreal triamcinolone for AMD CNVM underwent IVFA, BCVA...

Read More

The PHP-II (Automated Preferential Hyperacuity Perimeter) for Detection of CNV in Age-related Macular Degeneration (AMD)

Ruth Axer Siegel, MD (Petah Tikva, Israel), Irit Rosenblat, MD (Petah-tikva, Isreal), Anat Loewenstein, MD (Tel Aviv, Israel),* Ludmila Shani, MD (Beer-sheva, Isreal), Adiel Barak, MD (Tel-aviv, Isreal), Tova Lifshitz, MD (Beer-sheva, Isreal), Marina Shneck, MD (Beersheva, Isreal), Amira Springer, MD (Rehovot, Isreal), Ayala Pollack, MD (Rehovot, Israel), Michaela Goldstein, MD (Tel-aviv, Isreal), Joseph Ferentz, MD (Kfar-saba,...

Read More

Avastin Adjuvants in CNV Surgery

Joerg C. Schmidt, MD (Marburg, Germany), Stefan Mennel, MD (Marburg, Germany), Carsten Meyer, PD, MD (Marburg, Germany), Stefan Hoerle, MD (Marburg, Germany) PURPOSE: Subretinal CNV extraction and macular transposition can be offered to selected patients as a treatment option. When this surgery was first used, the development of PVR was the main postoperative complication, now CNV recurrence is the major problem. METHODS: During the last...

Read More

Triple Therapy: Photodynamic Therapy, Intravitreal Bevacizumab and Preservative Free Triamcinolone Acetonide for the Treatment of Exudative AMD

Arturo Santos, MD, PhD (Guadalajara, Mexico), Enrique A. Roig-Melo, MD PhD (Guadalajara, Mexico), Ramon Flores-Fuentes, MD (Guadalajara, Mexico), Juan C. Altamirano, MD (Guadalajara, Mexico) PURPOSE: To evaluate the feasibility and safety of the combination of photodynamic therapy with verteporfin (PDT), intravitreal Bevacizumab and preservative free Triamcinolone acetonide (PFTA) for the treatment of exudative AMD. METHODS: This is a...

Read More

CLEAR-IT 1: A Phase I Safety, Tolerability, and Bioactivity Study of Intravitreal VEGF Trap in Patients with Neovascular AMD

http://www.evrs.eu/medias/2006/congress/CLEAR-IT-1:-A-Phase-I-Safety,-Tolerability,-and-Bioactivity-Study-of-Intravitreal-VEGF-Trap-in-Patients-with-Neovascular-AMD.swf Quan Dong Nguyen, MD (Baltimore, MD),* David Browning, MD, PhD (Charlotte, NC),* Peter L. Sonkin, MD (Nashville, TN),* Seenu Hariprasad, MD (Chicago, IL),* Henry L. Hudson, MD, FACS (Tucson, AZ),* Karen Chu, (Tarrytown, NY),* Julia A. Haller, MD (Baltimore, MD), William F....

Read More

Thermal Laser Photocoagulation Combined with Intravitreal Triamcinolone Injection for Treatment of Choroidal Neovascularization

Edwin H. Ryan, MD (Minneapolis, MN), Lejla Mutapcic, BS (Rochester, MN), Jose S. Pulido, MD (Chicago, IL) PURPOSE: To determine via a retrospective review of treated patients whether thermal laser photocoagulation combined with intravitreal triamcinolone (IVTA) can safely and effectively reduce the risk of neovascular membrane recurrence and vision loss in patients with choroidal neovascularization (CNV). METHODS: We conducted a...

Read More

Intravitreal Bevacizumab (Avastin) Enhanced Pegaptanib (Macugen) Therapy for Choroidal Neovascularization in AMD: An Avastin Booster

http://www.evrs.eu/medias/2006/congress/Intravitreal-Bevacizumab-(Avastin)-Enhanced-Pegaptanib-(Macugen)-Therapy-for-Choroidal-Neovascularization-in-AMD:-An Avastin-Booster.swf Michael J. Tolentino, MD (Winter Haven, FL),* David M. Misch, MD (Winter Haven, FL), Adam S. Berger, MD (Winter Haven, FL), Suk Jin Moon, MD (Winter Haven, Fl) PURPOSE: The study purpose is to determine if bevacizumab combined with pegaptanib can harness the rapid...

Read More

Vision-specific Quality of Life at 12 Months in Subjects with or without Classic CNV Due to AMD: Phase III Clinical Trial of Ranibizumab (Lucentis)

Carl D. Regillo, MD, FACS (Philadelphia, PA),* Neil M. Bressler, MD (Baltimore, MD),* Jennifer T. Fine, PhD (South San Francisco, CA),* Chantal M. Dolan, PhD (South San Francisco, CA),* Claudine Marceau, PhD (Basel, Switzerland),* Tom S. Chang, MD (Pasadena, CA)* PURPOSE: To examine the effects of less frequent dosing of ranibizumab (LucentisTM) on patientreported visionspecific QoL through 12 months using the NEI-VFQ 25 in PIER, a phase...

Read More

Recurrence of Choroidal Neovascularization 18 Months after Photodynamic Therapy with or without Kenalog in Age-related Macular Degeneration

Michael J. Potter, MD (Vancouver, Canada),* Shelagh M. Szabo, BSc (Vancouver, Canada) PURPOSE: To compare the incidence of recurrence of CNV at 18 months after treatment with photodynamic therapy (PDT) with verteporfin, and PDT plus intravitreal Kenalog (IVT), in patients with age-related macular degeneration. METHODS: This is a prospective study of consecutive patients treated with PDT alone, or PDT plus IVT at baseline. Final treatment...

Read More

Combination Avastin and Reduced Fluence Photodynamic Therapy for Choroidal Neovascularization

http://www.evrs.eu/medias/2006/congress/Combination-Avastin-and-Reduced-Fluence-Photodynamic-Therapy-for-Choroidal-Neovascularization.swf David Callanan, MD (Arlington, TX),* Wayne Solley, MD (Arlington, TX) PURPOSE: The purpose of the study is to determine whether the combination of intravitreal Avastin and reduced fluence PDT is as effective as either treatment alone; and whether the combination therapy may reduce the number of treatments...

Read More

The Relationship Between Cataract Surgery, AMD and PDT

Ayala Pollack, MD (Rehovot, Israel), Amir Bukelman, MD (Rehovot, Israel), Gennady Landa, MD (Ashkelon, Israel), Yoel Greenwald, MD (Jerusalem, Israel), Haya Katz, MD (Rishon Lezion, Israel), Hana Leiba, MD (Yavneh, Israel) PURPOSE: To evaluate the relationship between cataract surgery, AMD, and PDT outcome. METHODS: All patients underwent both PDT for wet AMD, and cataract surgery by phacoemulsification. They were divided into three...

Read More

Combined Photodynamic Therapy with Verteporfin and Intravitreal Bevacizumab for Choroidal Neovascularization in Age-related Macular Degeneration

Gaurav K. Shah, MD (St. Louis, MO), Mandeep S. Dhalla, MD (St. Louis, MO), Kevin J. Blinder, MD (St. Louis, MO), Edwin H. Ryan, MD (Minneapolis, MN), Robert A. Mittra, MD (Minneapolis, MN), Asheesh Tewari, MD (St. Louis, MO) PURPOSE: To examine the 6-month results of a group of patients treated with combined photodynamic therapy (PDT) with verteporfin with intravitreal bevacizumab for choroidal neovascularization (CNV) secondary to...

Read More

The Role of Hyperthermia in Control of Sufoveal CNV: Stabilization of CNV with Low Recurrent Rate

Masood Naseripour, MD (Tehran, Iran), Kamran Manshaee, MD (Tehran, Iran), Pejman Bakhtiari, MD (Tehran, Iran), Shabnam Salimi, MD (Tehran, Iran) PURPOSE: To evaluate the role of hyperthermia in control of sufoveal CNV. METHODS: Method: the 93 eyes of 85 consecutive patients with angiographically proved CNV underwent TTT with diode laser emission at 810nm. Mean patients age was 74.0 ± 7.1 years (range: 55-88 years). 59 patients (69.4%)...

Read More

Agreement Among Canadian Retina Specialists in the Determination of Treatment Eligibility for Photodynamic Therapy in Age-related Macular Degeneration

Rajeev Hemant Muni, MD (Toronto, Canada), Mike Altaweel, MD (Madison, WI), Matt T. Tennant, MD (Edmonton, Canada), Bruce Weaver, BSc, MSc (Thunder Bay, Canada), Peter J. Kertes, MD, FRCS(C) (Toronto, Canada) PURPOSE: To determine the inter- and intra-observer agreement among Canadian retina specialists in the determination of treatment eligibility for photodynamic therapy and the angiographic classification of CNV. Agreement was also...

Read More

Combination Therapy for Wet Age-related Macular Degeneration Using Verteporfin Photodynamic Therapy and Intravitreal Bevacizumab

http://www.evrs.eu/medias/2006/congress/Combination-Therapy-for-Wet-Age-related-Macular-Degeneration-Using-Verteporfin-Photodynamic-Therapy-and-Intravitreal-Bevacizumab.swf Jose Dalma-Weiszhausz, MD (Mexico City, Mexico), Maura Lucy Abraham Marin, MD (Mexico City, Mexico), Carlos Fernando Cortes Luna, MD (Bogota, Colombia), Ana Suarez- Lincona, MD (Mexico City, Mexico), Griselda Alvarez-Rivera, MD (Mexico City, Mexico), Orlando Ustariz...

Read More

Intravitreal Bevacizumab Therapy for Neovascular Age-related Macular Degeneration: A Pilot Study

Virgilio Morales-Canton, MD (Mexico City, Mexico), Maura Lucy Abraham Marin, MD (Mexico City, Mexico), Carlos Fernando Cortes Luna, MD (Bogota, Colombia), Lidia Griselda Alvarez-Rivera, MD (Mexico City, Mexico), Myriam L Hernandez-Rojas, (Mexico City, Mexico), Hugo Quiroz-Mercado, MD (Mexico City, Mexico) PURPOSE: Evaluate efficacy and safety of intravitreal bevacizumab therapy for neovascular age-related macular degeneration...

Read More

Systemic Avastin Therapy for Neovascular Age Related Macular Degeneration

Jose Luis Rosales Meneses, MD, PhD (San Cristobal, Venezuela), Pedro P. Bonomo de Oliveira, MD (Sao Paulo, Brazil), Liz J. Florez Ovalles, MD (San Cristobal, Venezuela) PURPOSE: To evaluate the short term safety of systemic bevacizumab (Avastin) and its effects on visual acuity and subfoveal choroidal neovascularization in patients with neovascular age related macular degeneration. METHODS: Open label, single center, uncontrolled clinical...

Read More

Intravitreal Bevacizumab Compared with Photodynamic Therapy for Juxtafoveal Choroidal Neovascular Membranes in Age Related Macular Degeneration

Derek L. Barker, MD (Tallahassee, FL), H. Logan Brooks, MD (Tallahassee, FL), Robert L. Steinmetz, MD (Tallahassee, FL), Charles K. Newell, MD (Tallahassee, FL), Carmen A. Puliafito, MD (Miami, FL), Philip J. Rosenfeld, MD, PhD (Miami, FL) PURPOSE: Is bevacizumab more effective at preventing vision loss from juxtafoveal macular degeneration than photodynamic therapy? METHODS: A six month retrospective analysis of patients with juxtafoveal...

Read More

Treatment of Neovascular Age-related Macular Degeneration with Intravitreal Bevacizumab (Avastin®): Efficacy of 3 Consecutive Monthly Injections

Alex Melamud, MD (Durham, NC), Sharon Fekrat, MD (Durham, NC),* Jeff Taylor, MD (Raleigh, NC), Sandra S. Stinnett, PhD (Durham, NC) PURPOSE: Do 3 consecutive monthly injections of intravitreal bevacizumab (Avastin®) produce a sustained clinical improvement in eyes with neovascular agerelated macular degeneration? METHODS: We performed a retrospective review of consecutive eyes with all choroidal neovascular lesion subtypes due to...

Read More

A FA/ICG Analysis of the Retinal/Choroidal Vasculature and Choroidal Neovascular Membrane Complex Six Months Following Intravitreal Avastin Injections

Paul E. Tornambe, MD (Poway, CA)* PURPOSE: There are concerns that pan VEGF suppression may negatively effect the retinal and choroidal vasculature. The purpose of this paper is to describe what effect pulsed pan-VEGF inhibition using intravitreal Avastin has upon the retinal and choroidal vasculature and the six month response of the sub foveal choroidal neovascular membrane to intravitreal Avastin injections? METHODS: Thirty consecutive...

Read More

Time to Recurrence of AMD-related CNV Leakage after a Single Initial Intravitreous Injection Bevacizumab (Avastin®): Implications for a Retreatment

http://www.evrs.eu/medias/2006/congress/Time to Recurrence of AMD-related CNV Leakage after a Single Initial-Intravitreous-Injection-Bevacizumab-(Avastin):-Implications-for-a-Retreatment.swf Edgar L. Thomas, MD (Beverly Hills, CA)* PURPOSE: To evaluate the time to recurrent leakage on optical coherence tomography after a single initial intravitreous injection of bevacizumab (Avastin) for CNV in AMD METHODS: This is a retrospective chart...

Read More

Visual Outcome of Intravitreal Bevacizumab for Neovascular Age-related Macular Degeneration – Is Avastin Better Than Lucentis?

Charles E. Lyon, MD (Shreveport, LA), David H Ren, MD, PhD (Shreveport, LA) PURPOSE: To investigate the visual outcome of intravitreal bevacizumab in treating subfoveal choroidal neovascularization due to age-retlated macular degeneration. METHODS: An open label, nonrandomized, prospective observational study was done on patients with subfoveal choroidal neovascularization due to AMD regardless of lesion type and previous treatment. After...

Read More

Intravitreal Bevacizumab (Avastin) Treatment of Choroidal Neovascularization Secondary to Age-related Macular Degeneration

http://www.evrs.eu/medias/2006/congress/Intravitreal-Bevacizumab-(Avastin)-Treatment-of-Choroidal-Neovascularization-Secondary-to-Age-related-Macular-Degeneration.swf Richard F. Spaide, MD (New York, NY),* Ketan Laud, MD (New York, NY), Howard Fine, MD (New York, NY), James M. Klancnik, MD (New York, NY), Catherine Meyerle, MD (New York, NY), Lawrence Yannuzzi, MD (New York, NY), John Alan Sorenson, MD (New York, NY), Jason S. Slakter, MD...

Read More

Multifocal Electroretinographic Long-term Follow-up in 12 Cases of Minimally Classic or Occult SRNV in ARMD Treated with Pegaptanib Sodium (Macugen)

Andreas Lipski, MD (Essen, Germany), Norbert Bornfeld (Essen, Germany), Mete Gök, Dr. (Essen, Germany), Bernhard Jurklies, Priv.-Doz. Dr. (Essen, Germany) PURPOSE: Electrophysiological and clinical follow-up of central retinal function in patients with minimally classic or occult SRNV in wet ARMD undergoing intravitreal therapy with Pegaptanib-Natrium (Macugen). METHODS: Eight patients with minimally classic and five patients with occult...

Read More

Intravitreal Bevacizumab (Avastin®) for Primary Treatment of Neovascular AMD

http://www.evrs.eu/medias/2006/congress/Intravitreal-Bevacizumab-(Avastin)-for-Primary-Treatment-of-Neovascular-AMD.swf David F. Williams, MD, MBA (Minneapolis, MN), Steven R. Bennett, MD (Minneapolis, MN), Herbert L. Cantrill, MD (Minneapolis, MN), Jill B. Johnson, MD (Minneapolis, MN), Robert A. Mittra, MD (Minneapolis, MN), Robert C. Ramsay, MD (Minneapolis, MN), Edwin H. Ryan, MD (Minneapolis, MN), Sundeep Dev, MD (Minneapolis,...

Read More

Vascular Leakage as a Predictive Factor of Outcome of Photodynamic Therapy with Visudyne®

Jaco Lavinsky, MD (Porto Alegre, Brazil), Daniel Lavinsky, MD (Sao Paulo, Brazil), Fabio Lavinsky, MD (Ramat Gan, Israel) PURPOSE: Currently, there are several new therapeutic strategies for exudative AMD being studied, and the main target has been to occlude neovascularization and to obtain an antiangiogenic and antipermeability effect. Our purpose was to study the influence of vascular leakage on the angiographic outcome of Photodynamic...

Read More

Intravitreal Bevacizumab (Avastin) for the Treatment of Neovascular Age-related Macular Degeneration (AMD)

Alessandro A. Castellarin, MD (Santa Barbara, CA), Robert L. Avery, MD (Santa Barbara, CA),* Dante J. Pieramici, MD (Santa Barbara, CA),* Ma-an A. Nasir, MD (Santa Barbara, CA), Melvin D. Rabena, BS (Santa Barbara, CA), Matthew J. Giust, CRA (Santa Barbara, CA) PURPOSE: To report the safety and biologic effect of intravitreal bevacizumab in the treatment of neovascular age-related macular degeneration in patients followed for a minimum of 6...

Read More

Combined Photodynamic Therapy and Intravitreal Triamcinolone Injection for the Treatment of Subfoveal Choroidal Neovascularization

Noha Khater, (Cairo, Egypt), Hoda, MH Mostafa, MD (Cairo, Egypt), Mahmoud Soliman (Cairo, Egypt), Tamer Macky, MD (Cairo, Egypt) PURPOSE: To evaluate the outcomes of combined intravitreal triamcinolone (IVTA) and photodynamic therapy (PDT) in the treatment of subfoveal choroidal neovascularization (CNV) caused by age related macular degeneration (AMD) and myopia. METHODS: Fifteen eyes from 15 patients with subfoveal CNV caused by AMD (n=10)...

Read More

VeriTAS: Study Design and Baseline Characteristics for a Combination Therapy Trial in Wet AMD

Peter K. Kaiser, MD (Cleveland, OH)* PURPOSE: The VeriTAS study is designed to evaluate the efficacy and safety of verteporfin PDT combined with either intravitreal triamcinolone acetonide or pegaptanib sodium to treat subfoveal choroidal neovascularization (CNV) secondary to age-related macular degeneration (AMD). The 24-month randomized, double-masked VeriTAS study enrolled patients at 50 centers in the U.S. METHODS: Inclusion criteria:...

Read More

Combination Pegaptanib and Photodynamic Therapy for Subfoveal Choroidal Neovascularization Secondary to Age-related Macular Degeneration

ThucAnh Thi Ho, MD (Chicago, IL), Pauline Townsend Merrill, MD (Chicago, IL) PURPOSE: To evaluate the role of combined intravitreal pegaptanib and photodynamic therapy with verteporfin (PDT) in the management of subfoveal choroidal neovascularization (CNV) secondary to age-related macular degeneration (AMD). METHODS: We performed a retrospective review on 11 eyes of 11 patients treated with combined pegaptanib and PDT. Pre-treatment and...

Read More

Comparison Between Intravitreal Triamcinolone and Bevacizumab for Serous Ped and Occult Choroidal Neovascularization Secondary to AMD

David Hauser, MD (Kefar Bilu B, Israel), Yoel Greenvald, MD (Rehovot, Israel), Amir Bukelman, MD (Rehovot, Israel), Haya Katz, MD (Rehovot, Israel), Reut Parnes, MD (Rehovot, Israel), Nir Shoham, (Rehovot, Israel), Genady Landa, MD (Rehovot, Israel), Ayala Pollack, MD (Rehovot, Israel) PURPOSE: To compare the outcome of intravitreal triamcinolone (Kenalog) and intravitreal bevacizumab (Avastin) for eyes with serous PED and occult choroidal...

Read More

Prolonged Choroidal Hypofluorescence Following Verteporfin PDT Combined with Intravitreal Triamcinolone Acetate Injection for Agerelated CNVM

http://www.evrs.eu/medias/2006/congress/Prolonged-Choroidal-Hypofluorescence-Following-Verteporfin-PDT-Combined-with-Intravitreal-Triamcinolone-Acetate-Injection-for-Agerelated-CNVM.swf Jeffrey K. Luttrull, MD (Ventura, CA), Charles A Spink, CRA (Ventura, CA) PURPOSE: To determine the incidence and effect of prolonged choroidal hypofluorescence (PCH) following combined verteporfin photodynamic therapy and intravitreal triamcinolone acetate...

Read More

Expression of VEGF and Endostatin in Human Choroidal Neovascular Membranes Following Verteporfin Photodynamic Therapy

Salvatore Grisanti, MD (Tuebingen, Germany), Olcay Tatar, MD (Tuebingen, Germany), Kei Shinoda, MD, PhD (Tokyo, Japan), Annemarie Adam, (Tuebingen, Germany), Klaus Lucke, MB ChB (Bremen, Germany), Claus Eckardt, MD (Frankfurt, Germany), Peter Stalmans, MD, PhD (Leuven, Belgium), Tillmann Eckert, MD (Frankfurt, Germany), Silvia Bopp, MD (Bremen, Germany), Karl Ulrich Bartz-Schmidt (Tuebingen, Germany) PURPOSE: To evaluate the impact of...

Read More

Subretinal Surgery with the Combination RPE and Choroidal Transplantation for the Treatment of ARMD Related Visual Loss in a US Management Algorithm

Calvin A. Grant, MD (Oak Lawn, IL) PURPOSE: To offer submacular surgery with combined RPE/choroid graft for patients that are ineligible for PDT and anti-VEGF agents for possible visual rehab. METHODS: 12 consecutive patients underwent submacular surgery with combined RPE/choroid graft as a prospective case control series. The patients had profound visual loss as a result of fibrosis in the subretinal space and choroid or atrophy of the...

Read More

Six-month Follow-up on 50 Consecutive Patients with Intravitreal Bevacizumab Injections for Neovascular Age Related Macular Degeneration

http://www.evrs.eu/medias/2006/congress/Six-month-Follow-up-on-50-Consecutive-Patients-with-Intravitreal-Bevacizumab-Injections-for-Neovascular-Age-Related-Macular-Degeneration.swf Samira Khan, (Albany, NY), Paul M. Beer, MD (Albany, NY), Naomi S. Falk, MD (Albany, NY), Amjad Hammad, MD (Albany, NY), Martin O’Malley, MD (Albany, NY) PURPOSE: 6 months results of intravitreal Bevacizumab on patients with neovascular ARMD. METHODS: A...

Read More

Recurrent Choroidal Neovascularization after Macular Translocation Surgery with 360-degree Peripheral Retinectomy

http://www.evrs.eu/medias/2006/congress/Recurrent-Choroidal-Neovascularization-after-Macular-Translocation-Surgery-with-360-degree-Peripheral-Retinectomy.swf WINNER 2006 BAUSCH & LOMB RETINA FELLOWS’ FORUMRESEARCH AWARD Claxton Baer, MD (Durham, NC), Catherine Bowes Rickman, PhD (Durham, NC), Sunil Srivastava, MD (Atlanta, GA), Goldis Malek, PhD (Durham, NC), Sandra Stinnett, DrPH (Durham, NC), Cynthia A. Toth, MD (Durham,...

Read More

Intravitreally Injected Anti-VEGF Drugs Exert a Biological Effect in the Fellow Eye

http://www.evrs.eu/medias/2006/congress/Intravitreally-Injected-Anti-VEGF-Drugs-Exert-a-Biological-Effect-in-the-Fellow-Eye.swf Tongalp H. Tezel, MD (Louisville, KY), Charles C. Barr, MD (Louisville, KY), Henry J. Kaplan, MD (Louisville, KY) PURPOSE: To determine whether the intravitreal injection of anti-VEGF drugs (Kenalog, Macugen, Avastin) exert any biological effect in the fellow eyes of patients with bilateral exudative...

Read More

Results of a One Year Study of Feeder Vessel Therapy (FVT) in Age Related Macular Degeneration

Giovanni Staurenghi, MD (Milan, Italy), Chiara Veronese, MD (Mississauga, Canada),* Garzia Levi, MD (Milan, Italy), Paolo Danzi, MD (Brescia, Italy), Robert Flower, MD (Baltimore, MD), Robert G. Devenyi, MD (Toronto, Canada) PURPOSE: To compare near-IR laser-only FVT with ICG dye-enhanced photocoagulation (DEP) using a device that enables visualization of the FV during treatment in a clinical trial. METHODS: 40 subjects randomized to FVT or...

Read More

Retinal Pigment Epithelial Tears after Intraocular Bevacizumab (Avastin®) Injection for Neovascular Age-related Macular Degeneration

Clement K. Chan, MD (Palm Springs, CA), Carsten H. Meyer, MD (Marburg, Germany), Jeffrey G. Gross, MD (Columbia, SC), Prema Abraham, MD (Rapid City, SD),* Steven G. Lin, MD (Palm Springs, CA), Asha S.D. Nuthi, DO (Palm Springs, CA) PURPOSE: To report a case series of retinal pigment epithelial (RPE) tears after off-label intraocular bevacizumab (Avastin) for neovascular age-related macular degeneration. Acute RPE tears are known to occur...

Read More

Evaluation of Relationship Between VEGF Levels and Age Related Macular Degeneration

K.V. Chalam, MD, PhD (Jacksonville, FL), Shailesh Kumar Gupta, MD (Jacksonville, FL), Sandeep Grover, MD (Jacksonville, FL), Swati Agarwal, MD (Jacksonville, FL) PURPOSE: Evaluation of Relationship between VEGF levels and Age Related Macular Degeneration. METHODS: 27 aqueous humors samples were collected at multiple sessions from 19 eyes of 19 patients with choroidal neovascular membranes (CNV), secondary to age related macular...

Read More

The Value and Cost-effectiveness of Interventions for Subfoveal, Neovascular, Age-related Macular Degeneration (ARMD)

http://www.evrs.eu/medias/2006/congress/The-Value-and-Cost-effectiveness-of-Interventions-for-Subfoveal,-Neovascular,-Age-related-Macular-Degeneration-(ARMD).swf Melissa M. Brown, MD, MN, MBA (Flourtown, PA),* Gary C. Brown, MD, MBA (Wyndmoor, PA)* PURPOSE: To assess the value of interventions utilized for the treatment of subfoveal, neovascular, agerelated macular degeneration (ARMD) employing evidencebased data from clinical trials...

Read More

Photodynamic Therapy for Subfoveal Predominantly Hemorrhagic Choroidal Neovascular Lesion Secondary to Age-related Macular Degeneration

Francesco Boscia, MD (Bari, Italy), Ugo Introini, MD (Milano, Italy), Alfredo Pece, MD (Melegnano (mi), Italy), Francesco Prascina,  MD (Foggia, Italy), Michele Reibaldi, MD (Catania, Italy), Claudio Furino, (Bari, Italy), Caterina Papadopolou, MD (Bari, Italy), Giancarlo Sborgia, MD (Bari, Italy) PURPOSE: Large randomized clinical trials of laser photocoagulation, photodynamic therapy (PDT) with verteporfin and antiangiogenic drugs have...

Read More

Vision-specific Quality of Life at 12 Months in Predominantly Classic Neovascular AMD in ANCHOR: A Phase III Trial of Ranibizumab and Verteporfin PDT

Neil M. Bressler, MD (Baltimore, MD), Chantal M. Dolan, PhD (South San Francisco, CA),* Jennifer Fine, ScD (South San Francisco, CA),* Claudine Marceau, MBA, MSc (Basel, Switzerland),* Tom S. Chang, MD (Pasadena, CA)* PURPOSE: To examine the effects of ranibizumab (LucentisTM) on patient-reported vision-specific quality of life (QoL) using the NEI-VFQ 25 through 12 months in subjects with predominantly classic subfoveal choroidal...

Read More

Vision Improvement with Combination Low-fluence Photodynamic Therapy (LFPDT) and Intravitreal Injection

Gregory R. Blaha, MD, PhD (Peabody, MA), Jeffrey L. Marx, MD (Peabody, MA)* PURPOSE: To report our experience with combination low-fluence PDT. METHODS: An IRB-approved, retrospective chart review of all patients receiving low-fluence (50% standard) PDT (LFPDT) at our institution was performed. RESULTS: Twenty five eyes of 24 patients received LFPDT. Two eyes did not receive combination therapy, two received Macugen (Pegaptanib,...

Read More

Ranibizumab (LucentisTM) Vision-specific Quality of Life through 24 Months in Neovascular AMD Subjects in MARINA: A Phase III Clinical Trial

http://www.evrs.eu/medias/2006/congress/Ranibizumab-(LucentisTM)-Vision-specific-Quality-of-Life-through-24-Months-in-Neovascular-AMD-Subjects-in-MARINA:-A-Phase-III-Clinical-Trial.swf Tom S. Chang, MD (Pasadena, CA),* Jennifer T. Fine, PhD (South San Francisco, CA),* Chantal M. Dolan, PhD (San Francisco, CA),* Claudine Marceau, PhD (Basel, Switzerland),* Neil M. Bressler, MD (Baltimore, MD)* PURPOSE: To examine the effects of ranibizumab...

Read More

Triple Combination Therapy (Photodynamic Therapy with Intravitreal Bevacizumab and Subtenon Triamcinolone Acetonide) for Choroidal Neovascularization

Alay S. Banker, MD (Ahmedabad, India), J. Fernando Arevalo, MD, FACS (Caracas, Venezuela), Ajay Dudani, MD (Mumbai, India) PURPOSE: To determine the results of combination triple therapy for choroidal neovascularization (CNV). METHODS: Prospective pilot study of 11 consecutive eyes with new (previously untreated) CNV which were treated with photodynamic therapy (PDT) with visudyne along with intravitreal bevacizumab (1.25mg) and subtenon...

Read More

Open-label, Multicenter, Phase II Study Assessing the Safety and Efficacy of Same-day Verteporfin and Liquid Ranibizumab 0.5mg (PROTECT Study)

Sebastian Wolf, MD (Bern, Switzerland),* Thomas C. Hohman, PhD (East Hanover, NJ),* PROTECT Study Group PURPOSE: To evaluate the safety and explore the efficacy of same-day administration of verteporfin and intravitreal injection of liquid ranibizumab 0.5mg. METHODS: PROTECT is an open label, multicenter, Phase II, 9 month study, in patients with predominantly classic (n=13) or occult (n=19), subfoveal CNV secondary to AMD. Verteporfin was...

Read More

Sub Retinal Injection of Bevacizumab (Avastin) in Treating Neovascular Age Related Macular Degeneration, 25 Gauge Approach

http://www.evrs.eu/medias/2006/congress/Sub-Retinal-Injection-of-Bevacizumab-(Avastin)-in-Treating-Neovascular-Age-Related-Macular-Degeneration,-25-Gauge-Approach.swf http://www.evrs.eu/medias/2006/congress/Sub-Retinal-Injection-of-Bevacizumab-(Avastin)-in-Treating-Neovascular-Age-Related-Macular-Degeneration,-25-Gauge-Approach.flv Ehab N. El-Rayes, MD (Cairo, Egypt) PURPOSE: Experimental studies have demonstrated that vascular endothelial...

Read More

Macrophages Inhibit Neovascularization in a Murine Model of Agerelated Macular Degeneration (AMD)

Rajendra S. Apte, MD, PhD (St. Louis, MO), Thomas A. Ferguson, PhD (St. Louis, MO), Jennifer Richter, BS (St. Louis, MO), John Herndon, BS (St. Louis, MO) PURPOSE: CNV is the process by which abnormal blood vessels develop underneath the retina and lead to blindness in over 90% of patients with AMD. Although the precise etiology of CNV in AMD remains unknown, the macrophage component of the inflammatory response has been thought to be...

Read More

An OCT-guided Variable-dosing Regimen with LucentisTM (Ranibizumab) in Neovascular AMD: One Year Results from the PrONTO Study

http://www.evrs.eu/medias/2006/congress/An-OCT-guided-Variable-dosing-Regimen-with-LucentisTM-(Ranibizumab)-in-Neovascular-AMD:-One-Year-Results-from-the-PrONTO-Study.swf Philip J. Rosenfeld, MD, PhD (Miami, FL),* Carmen A. Puliafito, MD, MBA (Miami, FL),* Anne E. Fung, MD (San Francisco, CA),* Geeta A. Lalwani, MD (Miami, FL), Stephan Michels, MD (Vienna, Austria),* William J. Feuer, MS (Miami, FL) PURPOSE: To determine if an OCT-guided...

Read More

Correlation of Optical Coherence Tomography and Retinal Angiography in Patients Treated with Bevacizumab for Choridal Neovascular Membrane

Swati Agarwal, MD (Jacksonville, FL), Shailesh Gupta, MD (Jacksonville, FL), Sandeep Grover, MD (Jacksonville, FL), K.V. Chalam, MD, PhD (Jacksonville, FL), Sweta Tarigopula, BS (Jacksonville, FL) PURPOSE: To correlate the optical coherence tomography and Heidelberg retinal angiography findings in patients treated with intravitreal bevacizumab for choroidal neovascular membranes. METHODS: 12 patients with choroidal neovascular membranes...

Read More

PIER: Year 1 FA/OCT Results in a Study of Ranibizumab (LucentisTM) for Choroidal Neovascularization (CNV) Due to Agerelated Macular Degeneration (AMD)

http://www.evrs.eu/medias/2006/congress/PIER:-Year-1-FA-OCT-Results-in-a-Study-of-Ranibizumab-(LucentisTM)-for-Choroidal-Neovascularization-(CNV)-Due-to- Agerelated-Macular-Degeneration-(AMD).swf William F. Mieler, MD (Chicago, IL) PURPOSE: PIER is a 2-year study of the safety/efficacy of 0.3-and 0.5mg doses intravitreal ranibizumab, injected monthly for 3 doses and then every 3 months, vs. Sham injections in AMD patients with CNV lesions...

Read More

PIER: Year 1 Results of a Phase IIIB Study of Ranibizumab Efficacy and Safety in Choroidal Neovascularization Due to Age-related Macular Degeneration

http://www.evrs.eu/medias/2006/congress/PIER:-Year-1-Results-of-a-Phase-IIIB-Study-of-Ranibizumab- Efficacy-and-Safety-in-Choroidal-Neovascularization-Due-to-Age-related-Macular-Degeneration.swf Prema Abraham, MD (Rapid City, SD),* Huibin Yue, PhD (South San Francisco, CA),* Naveed Shams, MD, PhD (South San Francisco, CA)* PURPOSE: PIER is a 2-year study of the safety and efficacy of intravitreal injections of 2 different doses (0.3 and 0.5...

Read More

Intravitreal Ranibizumab (LucentisTM) Plus Verteporfin Photodynamic Therapy for Neovascular Age-related Macular Degeneration: FOCUS 2-year Results

http://www.evrs.eu/medias/2006/congress/Intravitreal-Ranibizumab-(LucentisTM)-Plus-Verteporfin- Photodynamic-Therapy-for-Neovascular-Age-related-Macular- Degeneration:-FOCUS-2-year-Results.swf Andrew N. Antoszyk, MD (Charlotte, NC),* Debbi Kotlovker, (San Francisco, CA),* Sharon O’Byrne, (San Francisco, CA)* PURPOSE: The 2-year FOCUS study compared the safety and efficacy of monthly intravitreal injections of ranibizumab (Lucentis) in...

Read More

Consistency of Effect of Ranibizumab at 2 Doses on Contrast Sensitivity in 3 Phase III and IIIB Studies of Patients with CNV Secondary to AMD

http://www.evrs.eu/medias/2006/congress/Consistency-of-Effect-of-Ranibizumab-at-2-Doses-on-Contrast- Sensitivity-in-3-Phase-III-and-IIIB-Studies-of-Patients-with-CNV- Secondary-to-AMD.swf Jean-Francois Korobelnik, MD (Bordeaux, France)* PURPOSE: To examine the consistency of effect of intravitreal ranibizumab on contrast sensitivity in three populations of patients with different subtypes of choroidal neovascular lesions: predominantly...

Read More

Two-year Efficacy and Safety Results from the MARINA Study

http://www.evrs.eu/medias/2006/congress/Two-year-Efficacy-and-Safety-Results-from-the-MARINA-Study.swf Ursula Schmidt-Erfurth, MD (Vienna, Austria), George A.Williams, MD (Royal Oak, MI), for the MARINA Study Group PURPOSE: The MARINA study is a 2-year, Phase III, multicenter, randomized, double-masked, sham injectioncontrolled study designed to evaluate the efficacy and safety of monthly intravitreal injections of ranibizumab used as a...

Read More

Combined Safety of Intravitreal Ranibizumab in Two Phase III Studies of Choroidal Neovascularization Secondary to Age-related Macular Degeneration

Paolo Lanzetta, MD (Udine, Italy),* MARINA and ANCHOR Study Groups PURPOSE: To examine the consistency of safety across two studies of ranibizumab in three populations of patients with different subtypes of choroidal neovascular lesions: predominantly classic, minimally classic and occult lesions with no classic component. METHODS: Ranibizumab has been tested in 2 Phase III, randomized, multicenter, double-masked, controlled studies of...

Read More

Spectral Domain Optical Coherence Tomography Provides New Insight into the Extent of Macular Pathology in Age-related Macular Degeneration

Cynthia A. Toth, MD (Durham, NC), Marcin Stopa, MD (Poznan, Poland), Joseph Izatt, PhD (Durham, NC),* Bradley A. Bower, PhD (Durham, NC), Brian Dodge, (Durham, NC) PURPOSE: Pathology data from three-dimensional imaging of the fundus with spectral domain optical coherence tomography (SDOCT) can be extracted, cross-correlated with conventional retinal imaging and retinal function data, and can be precisely monitored over time. Such data would...

Read More

Multifocal Electroretinogram Functional Aspects in Different Phenotypes of Age Related Macular Degeneration

Alain Zourdani, MD (Creteil, France), Patricia Haymann, MD (Creteil, France), Joelle Marciano, MD (Creteil, France), Eric Souied, MD (Creteil, France), Gabriel J. Coscas, MD (Creteil, France), Gisele Soubrane, MD (Creteil, France) PURPOSE: A pre requisite for a successful treatment of age related macular degeneration (AMD) requires preservation of functional macular photoreceptors. The aim of this study was to establish potential...

Read More

Combined Efficacy of Intravitreal Ranibizumab in Two Phase III Studies of Choroidal Neovascularization Secondary to Age-related Macular Degeneration

http://www.evrs.eu/medias/2006/congress/Combined-Efficacy-of-Intravitreal-Ranibizumab-in-Two-Phase-III-Studies-of-Choroidal-Neovascularization-Secondary-to-Age-related-Macular-Degeneration.swf Anat Loewenstein, MD (Tel Aviv, Israel),* MARINA and ANCHOR Study Group PURPOSE: Is Ranibizumab effective in the treatmentof CNV secondary to AMD? METHODS: Ranibizumab has been tested in two Phase III,randomized, multicenter, double-masked, controlled...

Read More

Active Choroidal Neovascularization without Subretinal or Intraretinal Fluid on OCT Imaging

http://www.evrs.eu/medias/2006/congress/Active-Choroidal-Neovascularization-without-Subretinal-or-Intraretinal-Fluid-on-OCT-Imaging.swf G. Baker Hubbard, MD (Atlanta, GA) METHODS: Retrospective chart review. RESULTS: Two cases of active CNV due to age-related macular degeneration (AMD) and one case of CNV secondary to juxtafoveal telangiectasis (JFT) were identified. The AMD cases had been previously treated for CNV. The JFT case was not...

Read More

Combined Photodynamic Therapy with Verteporfin and Intravitreal Bevacizumab for Subfoveal Choroidal Neovascularization in AMD

http://www.evrs.eu/medias/2006/congress/Combined-Photodynamic-Therapy-with-Verteporfin-and-Intravitreal-Bevacizumab-for-Subfoveal-Choroidal-Neovascularization-in-AMD.swf David M. Misch, MD (Winter Haven, FL), Michael J. Tolentino, MD (Winter Haven, FL),* Adam S. Berger, MD (Winter Haven, FL), Suk Jin Moon, MD (Winter Haven, FL) PURPOSE: To determine the safety and efficacy of combined intravitreal Bevacizumab (Avastin) with photodynamic...

Read More

Four Years Experience with Macular Translocation

Zoran Tomic Purpose: To report on our results with full macular translocation (FMT) in the treatment of ARMD. Methods: Retrospective study on 15 consecutive eyes that underwent FMT for the treatment of subfoveal CNV in ARMD. Results: Visual acuity improved by ≥ 2 lines Snellen in 6 operated eyes (40%), remained unchanged in 3 eyes (20%) and worsened in 6 (40%). Reading vision recovered in 5 eyes (33%) and maintained in 2 (13%)....

Read More

Limited Invasive Procedures to Treat CNV’s in ARMD

Frank Koch, MD, 1, Lars-Olof Hattenbach, MD, 1, Albert Augustin, MD, 2 – 1 University Eye Clinic Frankfurt/M., Germany, 2. Staedt. Kliniken Karlsruhe, Germany Purpose: To summarize the treatment potentials of steroid injections w/o laser coagulation for treatment of the macula in ARMD. Methods: Triamcinolone (0.4 to 20 mg) is injected intravitreally and/or subretinally. Subthreshold laser is applied transretinally or subretinally through...

Read More

Surgical Extraction of Choroidal Neovascular Membranes (CNVM)

Ziya Kapran, Tugrul Altan, Mehmet Çakır, Nur Acar, Yaprak B. Ünver, Aslı Utine, Zerrin Bayraktar Purpose: Evaluation of the results of surgical extraction of the choroidal neovascular membranes (CNVM). Methods: Four eyes of 4 patients who underwent surgical extraction of CNVM between July 2002 and July 2003 were retrospectively evaluated. Complications, visual prognosis, and recurrence rate were recorded. Results: The etiology of the...

Read More

Rheopheresis to Eradicate the Drusen – CNV Cascade

http://www.evrs.eu/medias/2005/congress/Rheopheresis-to-Eradicate-the-Drusen-CNV-Cascade.swf Frank Koch, MD, 1, Reiner Klingel, MD, 2, Cordula Fassbender, MD, 2 – 1 University Eye Clinic, Frankfurt/Main, Germany, 2 Apheresis Research Institute, Cologne, Germany Purpose: To update the current results of rheopheresis. Methods: Elimination of excact defined spectrum of high-molecular proteins from the blood circulation. The rheopheresis is...

Read More

Histological Charateristics of Neovascular Membranes in AMD after PDT: Comparison with Spontaneous Evolution, Laser Photocoagulation and Radiotherapy

http://www.evrs.eu/medias/2005/congress/Histological-charateristics-of-neovascular-membranes-in-AMD-after-PDT:-Comparison-with-spontaneous-evolution,-laser-photocoagulation-and-radiotherapy.swf Didier Ducournau, Nantes, France, Yvette Ducournau – Nantes, France Purpose: To describe and emphasize specific histological changes observed on removed neovascular membranes after PDT in order to understand the post treatment complication and the...

Read More

Photodynamic Therapy for Choroidal Neovascularization in Juvenile Disciform Macular Degeneration. Case Report of Four Icelandic Cases

http://www.evrs.eu/medias/2005/congress/Photodynamic-Therapy-for-Choroidal-Neovascularization-in-Juvenile-Disciform-Macular-Degeneration.-Case-Report-of-Four-Icelandic-Cases.swf Ingimundur Gislason, MD, Fridbert Jonasson, MD, Thordur Sverrisson, MD – Department of Ophthalmology, Landspitali University Hospital, Reykjavik, Iceland Purpose: To evaluate the result of PDT treatment for choroidal neovascularization in juvenile disciform...

Read More

Encouraging Results of Photodynamic Therapy with Verteporfin in a Clinical Patient Material of Age-Related Macular Degeneration and Choroidal Neovascularization

http://www.evrs.eu/medias/2005/congress/Encouraging-results-of-photodynamic-therapy-with-verteporfin-in-a-clinical-patient-material-of-age-related-macular-degeneration-and-choroidal-neovascularization.swf Christina Frennesson, MD, PhD, Sven Erik Nilsson, MD, PhD Purpose: To investigate the effects of photodynamic therapy (PDT) on sub- and juxtafoveal choroidal neovascularization (CNV) in age-related macular degeneration (AMD) in a clinical...

Read More

Hypothesis: Is Vitreous Adhesion a Risk Factor for CNV in AMD?

http://www.evrs.eu/medias/2005/congress/Hypothesis:-Is-vitreous-adhesion-a-risk-factor-for-CNV-in-AMD.swf Martine Mauget-Faÿsse, Maddalena Quaranta El Maftouhi, Margara Zanotele, François Devin Purpose: The relationships between posterior vitreous and retina have been poorly described in vivo in exudative AMD. In a previous study (ARVO 2003), high prevalence of abnormalities of the vitreo-retinal interface have been found in exudative AMD...

Read More

Choroidal Neovascularization – from Mice to Man

Lennart Berglin, MD, PhD – St. Erik Eye Hospital, Karolinska Institutet, Stockholm, Sweden Many signs indicate an inflammatory reaction and a molecular breakdown of the bloodretina barrier in Bruchs membrane with age in choroidal neovascularization (CNV). The vascular response has many similarities with an unspecific wound healing process elsewhere in the body. New vessel growth (angiogenesis) can be triggered by a switch in a normally...

Read More

Full Macular Translocation vs. Verteporfin Photodynamic Therapy for Neovascular Age-Related Macular Degeneration – Intermediate Results of a Prospective, Controlled, Randomized Pilot Study

F. Gelisken, K. U. Bartz-Schmidt for the Tuebingen Study Group Purpose: To report the change of the mean visual acuity of the patients enrolled in the Full Macular Translocation (FMT) vs. Verteporfin Photodynamic Therapy (PDT) study for subfoveal, predominantly classic choroidal neovascularization (CNV) secondary to age-related macular degeneration (AMD). Design Monocenter, prospective, controlled, randomized, clinical, pilot study....

Read More
content top